Tech Company Financing Transactions
Noxopharm Funding Round
On 2/27/2026, Noxopharm raised $5 million in investment from Acuity Ventures.
Transaction Overview
Company Name
Announced On
2/27/2026
Transaction Type
Debt
Amount
$5,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
159 Ridgecrop Drive 71
Castle Hill, NSW, 2154
Australia
Castle Hill, NSW, 2154
Australia
Phone
Website
Email Address
Overview
Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines. The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms -- Sofra� (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma� (oncology).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gisela Mautner
Chief Financial Officer
Shawn Van Boheemen
Chief Scientific Officer
Olivier Laczka
Browse more venture capital transactions:
Prev: 2/27/2026: Encord venture capital transaction
Next: 2/27/2026: Made With Intent venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC transactions reported here are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs